JP2010270124A5 - - Google Patents

Download PDF

Info

Publication number: JP2010270124A5
Authority: JP; Japan
Prior art keywords: pharmaceutically acceptable; dmxaa; dimethylxanthenone; acetic acid; acceptable salt
Prior art date: 2010-07-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2010151115A

Other languages

English (en)

Japanese (ja)

Other versions

JP2010270124A (ja

Filing date

2010-07-01

Publication date

2011-01-20

2001-09-03 Priority claimed from GBGB0121285.1A external-priority patent/GB0121285D0/en

2010-07-01 Application filed filed Critical

2010-12-02 Publication of JP2010270124A publication Critical patent/JP2010270124A/ja

2011-01-20 Publication of JP2010270124A5 publication Critical patent/JP2010270124A5/ja

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims 9
XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 claims 9
150000003839 salts Chemical class 0.000 claims 8
206010028980 Neoplasm Diseases 0.000 claims 4
201000011510 cancer Diseases 0.000 claims 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
229960004316 cisplatin Drugs 0.000 claims 4
230000002708 enhancing effect Effects 0.000 claims 4
230000001747 exhibiting effect Effects 0.000 claims 4
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
229960004397 cyclophosphamide Drugs 0.000 claims 3
239000003937 drug carrier Substances 0.000 claims 2
238000000034 method Methods 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
239000000825 pharmaceutical preparation Substances 0.000 claims 2
239000003814 drug Substances 0.000 claims 1
238000001990 intravenous administration Methods 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
229950008737 vadimezan Drugs 0.000 claims 1

JP2010151115A 2001-09-03 2010-07-01 抗癌組み合わせ Pending JP2010270124A (ja)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0121285.1A GB0121285D0 (en)	2001-09-03	2001-09-03	Anti-cancer combinations

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2003524567A Division JP2005509599A (ja)	2001-09-03	2002-09-03	抗癌組み合わせ

Publications (2)

Publication Number	Publication Date
JP2010270124A JP2010270124A (ja)	2010-12-02
JP2010270124A5 true JP2010270124A5 (2)	2011-01-20

Family

ID=9921418

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2003524567A Ceased JP2005509599A (ja)	2001-09-03	2002-09-03	抗癌組み合わせ
JP2009133903A Pending JP2009263371A (ja)	2001-09-03	2009-06-03	抗癌組み合わせ
JP2010151115A Pending JP2010270124A (ja)	2001-09-03	2010-07-01	抗癌組み合わせ

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
JP2003524567A Ceased JP2005509599A (ja)	2001-09-03	2002-09-03	抗癌組み合わせ
JP2009133903A Pending JP2009263371A (ja)	2001-09-03	2009-06-03	抗癌組み合わせ

Country Status (23)

Country	Link
US (6)	US7863322B2 (2)
EP (3)	EP1423105B9 (2)
JP (3)	JP2005509599A (2)
CN (5)	CN101596186A (2)
AT (1)	ATE415963T1 (2)
AU (1)	AU2002324143B2 (2)
BR (1)	BR0212258A (2)
CA (1)	CA2458459A1 (2)
CY (1)	CY1110426T1 (2)
DE (1)	DE60230159D1 (2)
DK (1)	DK1423105T3 (2)
EA (3)	EA010857B1 (2)
ES (1)	ES2321283T3 (2)
GB (1)	GB0121285D0 (2)
IL (1)	IL160178A0 (2)
IS (1)	IS7144A (2)
MX (1)	MXPA04002004A (2)
NO (1)	NO20040591L (2)
NZ (5)	NZ567456A (2)
PT (1)	PT1423105E (2)
SI (1)	SI1423105T1 (2)
WO (1)	WO2003020259A2 (2)
ZA (1)	ZA200401078B (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
JP4638098B2 (ja) *	1999-06-14	2011-02-23	キャンサー・リサーチ・テクノロジー・リミテッド	癌治療
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
AU2001282717A1 (en)	2000-07-28	2002-02-13	Cancer Research Technology Limited	Cancer treatment by combination therapy
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
GB0202544D0 (en)	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
GB2386836B (en)	2002-03-22	2006-07-26	Cancer Res Ventures Ltd	Anti-cancer combinations
GB2394658A (en)	2002-11-01	2004-05-05	Cancer Rec Tech Ltd	Oral anti-cancer composition
GB0321999D0 (en) *	2003-09-19	2003-10-22	Cancer Rec Tech Ltd	Anti-cancer combinations
DE602004016376D1 (de)	2003-11-13	2008-10-16	Pharma Mar Sau	Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
RS50510B (sr)	2004-10-29	2010-03-02	Pharma Mar S.A., Sociedad Unipersonal	Formulacije koje sadrže ekteinascidin i disaharid
GB0517387D0 (en) *	2005-08-26	2005-10-05	Antisoma Res Ltd	Combinations for the treatment of cancer
CA2620436A1 (en) *	2005-08-26	2007-03-01	Antisoma Plc	Combinations comprising dmxaa for the treatment of cancer
GB0522082D0 (en)	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
GB0625283D0 (en) *	2006-12-19	2007-01-24	Cyclacel Ltd	Combination
CA2708149A1 (en) *	2007-12-13	2009-06-18	Novartis Ag	Combinations of therapeutic agents for treating cancer
CN101279967B (zh) *	2008-05-29	2010-11-10	武汉远大制药集团有限公司	一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途
CN102203132A (zh)	2008-08-25	2011-09-28	安普利穆尼股份有限公司	Pd-1拮抗剂的组合物和使用方法
US20100068302A1 (en) *	2008-09-17	2010-03-18	Traslational Cancer Drugs Pharma, S.L.	Methods and compositions for the treatment of cancer
US20120129895A1 (en) *	2009-08-11	2012-05-24	Colleen Conway	Methods of treatment
DK3327148T3 (da)	2010-06-18	2021-04-12	Myriad Genetics Inc	Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle
ES2704303T3 (es)	2010-08-24	2019-03-15	Dana Farber Cancer Inst Inc	Procedimientos para la predicción de una respuesta contra el cáncer
CN102786509B (zh) *	2011-05-16	2016-06-01	杭州民生药业有限公司	2-(5,6-二甲基呫吨酮-4-基)-乙酸的衍生物及其制备方法和用途
EP4563709A3 (en)	2011-06-17	2025-09-03	Myriad Genetics, Inc.	Methods and materials for assessing allelic imbalance
CN107267598B (zh)	2011-12-21	2022-03-25	美瑞德生物工程公司	用于评估杂合性丢失的方法与材料
EP2617421A1 (en) *	2012-01-20	2013-07-24	Isofol Medical AB	Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
WO2013130347A1 (en)	2012-02-23	2013-09-06	The Children's Hospital Corporation	Methods for predicting anti-cancer response
ES2658867T3 (es)	2012-06-07	2018-03-12	Institut Curie	Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
WO2014160080A1 (en)	2013-03-14	2014-10-02	Children's Medical Center Corporation	Cancer diagnosis, treatment selection and treatment
DK2981624T3 (da)	2013-04-05	2020-03-02	Myriad Genetics Inc	Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
US20160067182A1 (en) *	2013-04-09	2016-03-10	Merrimack Pharmaceuticals, Inc.	Methods and compositions for improving outcomes of liposomal chemotherapy
JP2016538344A (ja) *	2013-11-19	2016-12-08	ザ・ユニバーシティ・オブ・シカゴＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣｈｉｃａｇｏ	癌処置としてのｓｔｉｎｇアゴニストの使用
EP3080292B1 (en)	2013-12-09	2022-02-02	Institut Curie	Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP4234711B1 (en)	2014-08-15	2025-05-28	Myriad Genetics, Inc.	Methods and materials for assessing homologous recombination deficiency
EP4141127B1 (en)	2021-08-30	2024-10-09	Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln	Method for assessing homologous recombination deficiency in ovarian cancer cells
CN115282140B (zh) *	2022-02-07	2024-03-08	南京市儿童医院	Aki治疗剂及dmxaa在制备该治疗剂中的应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3655470A (en) *	1969-03-29	1972-04-11	Toa Gosei Chem Ind	Process for the production of a foamed thermoplastic resin sheet
DE2015265A1 (de)	1969-03-29	1970-10-08	Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan)	Arylalkansäuren und Verfahren zu deren Herstellung
US4565806A (en) *	1981-08-18	1986-01-21	Setaelae Kai M E	Composition and method for rational treatment of cancer
FR2516922A1 (fr) *	1981-11-25	1983-05-27	Lipha	Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
ATE92499T1 (de) *	1984-12-04	1993-08-15	Lilly Co Eli	Tumorbehandlung bei saeugetieren.
US4704355A (en) *	1985-03-27	1987-11-03	New Horizons Diagnostics Corporation	Assay utilizing ATP encapsulated within liposome particles
US5281620A (en) *	1986-12-23	1994-01-25	Cancer Research Campaign Technology Limited	Compounds having antitumor and antibacterial properties
JP2672101B2 (ja)	1986-12-23	1997-11-05	ディーエフシーニュージーランドリミテッド	キサンテノン−４−酢酸誘導体
JPH01193227A (ja)	1988-01-29	1989-08-03	Res Dev Corp Of Japan	癌免疫療法補助剤
US5126129A (en) *	1988-05-23	1992-06-30	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Cancer therapy using interleukin-2 and flavone compounds
US5075287A (en)	1989-03-03	1991-12-24	Nisshin Oil Mills, Inc.	Muramyl peptide derivatives and immunoregulating compositions containing them
CA2025907A1 (en)	1989-09-21	1991-03-22	Franklin D. Collins	Method of transporting compositions across the blood brain barrier
US5250296A (en)	1990-11-29	1993-10-05	Takeda Chemical Industries, Ltd.	Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
EP0551200A1 (en)	1992-01-07	1993-07-14	National University Of Singapore	Protein phosphatase inhibitors for use in therapy
CA2086874E (en)	1992-08-03	2000-01-04	Renzo Mauro Canetta	Methods for administration of taxol
GB9308166D0 (en) *	1993-04-20	1993-06-02	Cancer Res Campaign Tech	Cancer therapy
GB9320484D0 (en)	1993-10-05	1993-11-24	Wellcome Found	Pharmaceutical combinations
DE4417742A1 (de) *	1994-05-20	1995-11-23	Bayer Ag	Nicht-systemische Bekämpfung von Parasiten
US5620875A (en) *	1995-02-17	1997-04-15	University Of Portland	Transfer of taxol from yew tree cuttings into a culture medium over time
WO1996032418A1 (en)	1995-04-13	1996-10-17	Laboratoires Om S.A.	Anti-cd14 antibodies for use in the induction of il-10 secretion
EP0743064A1 (en)	1995-05-17	1996-11-20	Eli Lilly And Company	Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease
JPH0940690A (ja)	1995-05-23	1997-02-10	Yutaka Sashita	ステロイド配糖体及びこれを有効成分とする医薬
WO1997004761A1 (en)	1995-07-28	1997-02-13	Trustees Of Boston University	Methods and compositions for treating cell proliferative disorders
US5977077A (en)	1995-08-28	1999-11-02	Interlab Corporation	Xanthone analogs for the treatment of infectious diseases
US5863904A (en) *	1995-09-26	1999-01-26	The University Of Michigan	Methods for treating cancers and restenosis with P21
US5817684A (en) *	1996-12-13	1998-10-06	Eli Lilly And Company	Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
UA47505C2 (uk)	1996-12-13	2002-07-15	Елі Ліллі Енд Компані	Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну
AU5792398A (en)	1996-12-13	1998-07-03	Eli Lilly And Company	Leukotriene antagonists for treatment or inhibition of gout
NZ337376A (en)	1997-03-11	2002-02-01	Aeterna Lab Inc	Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
AU6572298A (en)	1997-03-21	1998-10-20	Eli Lilly And Company	Leukotriene antagonists useful for treating ischemia reperfusion injury
HUP9904672A2 (hu) *	1997-03-21	2000-05-28	Eli Lilly And Co.	Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
AU6764798A (en)	1997-03-21	1998-10-20	Eli Lilly And Company	Leukotriene antagonists useful for treating cystic fibrosis
AU6570798A (en)	1997-03-21	1998-10-20	Eli Lilly And Company	Leukotriene antagonists useful for treating gingivitis
US5998454A (en)	1997-03-21	1999-12-07	Eli Lilly And Company	Leukotriene antagonists useful for treating iritis
WO1998042345A1 (en)	1997-03-21	1998-10-01	Eli Lilly And Company	Leukotriene antagonists useful for treating cerebral focal stroke
WO1998042335A1 (en)	1997-03-21	1998-10-01	Eli Lilly And Company	Leukotriene antagonists useful for treating gout
US5914340A (en)	1997-03-21	1999-06-22	Eli Lilly And Company	Leukotriene antagonists useful for treating dermatoses
DE19721211A1 (de)	1997-05-21	1998-11-26	Lindner Sen Wolfgang Dr Med	Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren
WO2000010600A2 (en)	1998-08-24	2000-03-02	Maxim Pharmaceuticals, Inc.	Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
EP1119361A4 (en)	1998-09-10	2006-10-04	Magainin Pharma	TREATMENT OF CARCINOMA WITH SQUALAMINE IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
AUPP609198A0 (en)	1998-09-22	1998-10-15	Curtin University Of Technology	Use of non-peptidyl compounds for the treatment of insulin related ailments
US6174873B1 (en) *	1998-11-04	2001-01-16	Supergen, Inc.	Oral administration of adenosine analogs
GB9903404D0 (en)	1999-02-16	1999-04-07	Angiogene Pharm Ltd	Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
ATE289586T1 (de) *	1999-03-01	2005-03-15	Pfizer Prod Inc	Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
JP4638098B2 (ja) *	1999-06-14	2011-02-23	キャンサー・リサーチ・テクノロジー・リミテッド	癌治療
US6806257B1 (en) *	1999-10-20	2004-10-19	Board Of Trustees Of Southern Illinois University	Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
PL355172A1 (en)	1999-11-11	2004-04-05	Eli Lilly And Company	Oncolytic combinations for the treatment of cancer
WO2001034135A2 (en)	1999-11-11	2001-05-17	Eli Lilly And Company	Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en)	1999-11-11	2001-05-17	Eli Lilly And Company	Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en)	1999-11-11	2001-05-17	Eli Lilly And Company	Oncolytic combinations for the treatment of cancer
AU3822701A (en) *	2000-02-17	2001-08-27	Merck & Co., Inc.	Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2001247459A (ja)	2000-03-03	2001-09-11	Oakland Uniservices Ltd	癌の組み合わせ療法
AU2001282717A1 (en) *	2000-07-28	2002-02-13	Cancer Research Technology Limited	Cancer treatment by combination therapy
GB0121285D0 (en) *	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
GB2386836B (en) *	2002-03-22	2006-07-26	Cancer Res Ventures Ltd	Anti-cancer combinations
GB2394658A (en)	2002-11-01	2004-05-05	Cancer Rec Tech Ltd	Oral anti-cancer composition
GB0321999D0 (en)	2003-09-19	2003-10-22	Cancer Rec Tech Ltd	Anti-cancer combinations
GT200500186A (es) *	2004-07-07	2006-03-02		Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
CA2620436A1 (en)	2005-08-26	2007-03-01	Antisoma Plc	Combinations comprising dmxaa for the treatment of cancer
GB0517387D0 (en)	2005-08-26	2005-10-05	Antisoma Res Ltd	Combinations for the treatment of cancer
CA2702301A1 (en)	2007-10-23	2009-04-30	Antisoma Research Limited	Crystalline forms of dmxaa sodium salt

2001
- 2001-09-03 GB GBGB0121285.1A patent/GB0121285D0/en not_active Ceased
2002
- 2002-09-03 ES ES02758562T patent/ES2321283T3/es not_active Expired - Lifetime
- 2002-09-03 EA EA200601118A patent/EA010857B1/ru not_active IP Right Cessation
- 2002-09-03 DE DE60230159T patent/DE60230159D1/de not_active Expired - Lifetime
- 2002-09-03 NZ NZ567456A patent/NZ567456A/en not_active IP Right Cessation
- 2002-09-03 EP EP02758562A patent/EP1423105B9/en not_active Expired - Lifetime
- 2002-09-03 CA CA002458459A patent/CA2458459A1/en not_active Abandoned
- 2002-09-03 DK DK02758562T patent/DK1423105T3/da active
- 2002-09-03 NZ NZ576925A patent/NZ576925A/en not_active IP Right Cessation
- 2002-09-03 SI SI200230798T patent/SI1423105T1/sl unknown
- 2002-09-03 BR BR0212258-8A patent/BR0212258A/pt not_active IP Right Cessation
- 2002-09-03 NZ NZ554093A patent/NZ554093A/en not_active IP Right Cessation
- 2002-09-03 AT AT02758562T patent/ATE415963T1/de active
- 2002-09-03 EA EA200801611A patent/EA200801611A1/ru unknown
- 2002-09-03 MX MXPA04002004A patent/MXPA04002004A/es active IP Right Grant
- 2002-09-03 EP EP10001750A patent/EP2236134A1/en not_active Withdrawn
- 2002-09-03 CN CNA2009101604099A patent/CN101596186A/zh active Pending
- 2002-09-03 CN CNB028172574A patent/CN100536840C/zh not_active Expired - Fee Related
- 2002-09-03 WO PCT/GB2002/004025 patent/WO2003020259A2/en not_active Ceased
- 2002-09-03 PT PT02758562T patent/PT1423105E/pt unknown
- 2002-09-03 EA EA200400370A patent/EA008056B1/ru not_active IP Right Cessation
- 2002-09-03 CN CNA2009101604084A patent/CN101607087A/zh active Pending
- 2002-09-03 NZ NZ546573A patent/NZ546573A/en not_active IP Right Cessation
- 2002-09-03 CN CNA2006101513931A patent/CN1994287A/zh active Pending
- 2002-09-03 CN CNA2009101604101A patent/CN101596187A/zh active Pending
- 2002-09-03 NZ NZ531045A patent/NZ531045A/en not_active IP Right Cessation
- 2002-09-03 AU AU2002324143A patent/AU2002324143B2/en not_active Ceased
- 2002-09-03 JP JP2003524567A patent/JP2005509599A/ja not_active Ceased
- 2002-09-03 IL IL16017802A patent/IL160178A0/xx unknown
- 2002-09-03 EP EP06077049A patent/EP1759694A3/en not_active Withdrawn
2004
- 2004-02-06 IS IS7144A patent/IS7144A/is unknown
- 2004-02-10 ZA ZA200401078A patent/ZA200401078B/en unknown
- 2004-02-10 NO NO20040591A patent/NO20040591L/no unknown
- 2004-03-02 US US10/790,943 patent/US7863322B2/en not_active Expired - Fee Related
2006
- 2006-11-03 US US11/592,678 patent/US20070060637A1/en not_active Abandoned
2007
- 2007-07-30 US US11/830,650 patent/US7868039B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,668 patent/US7863320B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,677 patent/US7863321B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,659 patent/US7868040B2/en not_active Expired - Fee Related
2008
- 2008-12-31 CY CY20081101516T patent/CY1110426T1/el unknown
2009
- 2009-06-03 JP JP2009133903A patent/JP2009263371A/ja active Pending
2010
- 2010-07-01 JP JP2010151115A patent/JP2010270124A/ja active Pending

Publication	Publication Date	Title
JP2010270124A5 (2)	2011-01-20
JP2012255026A5 (2)	2013-02-21
JP2013534248A5 (2)	2014-10-02
JP2014515373A5 (2)	2015-07-16
JP2015530389A5 (2)	2017-03-09
RU2013121788A (ru)	2014-12-27	Ингибиторы репликации вич
JP2013507415A5 (2)	2014-04-24
JP2020521797A5 (2)	2021-07-26
JP2013518107A5 (2)	2014-03-13
JP2009502743A5 (2)	2009-08-13
JP2014521735A5 (2)	2015-09-10
JP2012532874A5 (2)	2013-08-15
JP2001247459A5 (2)	2006-12-07
JP2013509429A5 (2)	2013-12-05
JP2012193216A5 (2)	2012-11-22
JP2015529234A5 (2)	2016-11-10
JP2013509411A5 (2)	2013-10-10
RU2017134443A (ru)	2019-04-04	Способ лечения с применением традипитанта
JP2013532729A5 (2)	2014-09-18
HK1206246A1 (en)	2016-01-08	Use of high dose laquinimod for treating multiple sclerosis
JP2012236834A5 (2)	2013-01-24
JP2013541583A5 (2)	2014-10-09
JP2019535760A5 (ja)	2020-12-24	ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法
JP2014530181A5 (2)	2015-10-01
JP2012522841A5 (2)	2013-05-23